Company intelligence / Profile preview

Vivlia

Seattle, Washington, United Statesvivlia.co.za ↗

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Vilya has developed and validated an AI-driven platform to design novel macrocycles with enhanced drug-like properties. The approach has been validated by recent peer-reviewed publications but no clinical-stage programs have been announced as of June 2025.

Therapeutic areas: Other
Modalities: Macrocyclic drugsPeptidesSmall molecule (related)Biologic (related)
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Vivlia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivlia.

Explore the full profile